Why the study?
Does aggressive therapy including pleuropericardial window improve survival in patients with disseminated breast cancer and cardiac tamponade?
Does aggressive therapy including pleuropericardial window improve survival in patients with disseminated breast cancer and cardiac tamponade?
Answers are grounded in this paper and cite their sources.
Aggressive therapy with a pleuropericardial window in patients with cardiac tamponade and breast cancer can lead to prolonged survival.
Six patients with disseminated breast cancer and cardiac tamponade were treated with a pleuropericardial window and in four patients with systemic chemotherapy. The median survival of these six patients was 17 months (range 1-50 months). These results indicate that aggressive therapy in patients with cardiac tamponade and breast cancer can lead to prolonged survivals.
No takes yet. Share an insight, caveat, or question.
Bitran et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: